US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.56 against a street estimate of 0.32 — a beat of 75.0%.
Analysts rate Kiniksa Pharmaceuticals Ltd a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $109.43.
CONFIDENT ARCALYST growth remained strong, lifting 2026 revenue guidance above $1 billion. KPL-387 enrollment is progressing toward second-half 2027 pivotal data, while KPL-1161 Phase I is planned by year-end. Q3 FY26 Analysts focused on KPL-387 timing, ARCALYST penetration, prescribing trends and future capital deployment. Management highlighted enrollment momentum, targeted spending and broad treatment opportunity. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 8.93% |
| Rubric Capital Management LP | 5.13% |
| Baker Bros Advisors LP | 3.63% |
| BlackRock Inc | 3.51% |
| TANG CAPITAL MANAGEMENT LLC | 2.90% |
| Vanguard Portfolio Management, LLC | 2.45% |
| Vanguard Capital Management, LLC | 1.74% |
| Morgan Stanley - Brokerage Accounts | 1.30% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $285,970 thousand, up from $180,855 thousand in the third quarter of 2025. • Nine-month 2026 reven | 2026-10-27 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $286.0 million, up from $180.9 million in Q3 2025; all revenue was product revenue. • ARCALYST net prod | 2026-10-27 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Kiniksa appointed Ross Moat as President and Chief Operating Officer, effective October 17, 2026. • Effective January 1, 2027, hi | 2026-10-22 |
| Quarterly report · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Product Revenue (6 months ended June 30, 2026): $457.9 million | 2026-07-28 |
| Results announced · Q3 2026 KINIKSKA PHARMACEUTICALS - Q2 2026 SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $243.6 million vs. $156.8 million in Q2 2025 (+55% YoY) • Q2 20 | 2026-07-28 |
| Shareholder vote results · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SHAREHOLDER MEETING SUMMARY HEADLINE NUMBERS • Annual Meeting held May 29, 2026 with quorum present • T | 2026-05-29 |
| Material agreement · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – FORM 8-K SUMMARY May 21, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Kiniksa Pharmaceuticals Internationa | 2026-05-26 |
| Board / officer change · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC - DOCUMENT SUMMARY HEADLINE NUMBERS • Filing Date: April 30, 2026 (Form 8-K - Current Report) • Company: | 2026-05-01 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 ARCALYST revenue guidance raised to $1.045–$1.050 billion Kiniksa reported strong third-quarter 2026 results, driven by ARCALYST for recurrent pericarditis. Revenue rose 58% year over year to $286.0 million, from $180.9 million. Net income increase | 2026-10-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kiniksa Pharmaceuticals Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.